Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase

Abstract

Aim. To analyse resistance to imatinib therapy, efficacy and safety of dasatinib.
Material and methods. A total of 18 patients with chronic myeloid leukemia (CML) in a chronic stage received dasatinib for 9-30 months (median 30 months) to September 2008.
Results. Lethal outcomes during dasatinib treatment were absent. To September 2008, 16(89%) patients were alive, 2(11%) patients died of the disease progression after dasatinib discontinuation. A complete clinicohematological response was observed in all the patients. Major cytogenetic, complete cytogenetic, major molecular, complete molecular responses were achieved in 12(67%), 10(55%), 7(39%) and 5(28%) patients, respectively. Hematological and non-hematological toxicity occurred in 9(50%) patients. Now 12(67%) patients continue dasatinib treatment, in 6(33%) patients the drug was discontinued.
Conclusion. The results from trials in Russian Hematological Research Center are the same as in the international study. Dasatinib is effective and well tolerated therapeutic option for imatinib-resistant patients with a chronic phase of CML.

References

  1. Kantarjian H., Pasquini R., Hamerschlak N. et al. Dasatinib or high-dose imatinib for with chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007; 109 (12): 5143-5150.
  2. Stephen G., O'Brien S. G., Guilhot F. et al. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate, of transformation and increased rate of major molecular response in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with Imatinib. Blood 2008; 112 (11): 76, abstr. 186.
  3. Shah N. P. DASATINIB. Drugs of Today 2007; 43 (1): 5-12.
  4. Shah N. P., Tran C., Lee F. Y. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401.
  5. Donato N. Activity of a novel turosine kinase inhibitor BMS-354825 on STI571 sensitive and resistant CML cells. Bristol-Myers Squibb, Jan 02, 2003. BMS Document Control N. 930003220.
  6. O'Harre T., Walters D. K., Stoffregen E. P. et al. Com-bind Abl inhibition therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin. Cancer Res. 2005; 11: 6987-6993.
  7. Tokarski J., Newitt J., Lee F. The crustal structure of ABL kinase with BMS-354825, a dual SRC/ABL kinase inhibitor. Blood 2004; 104: 160a.
  8. Sokal J. E., Cox E. B., Baccarani M. et al. Blood 1984; 63; 789-799.
  9. Туркина А. Г. Клиническое значение молекулярно-генетических и иммунофенотипических характеристик хронического миелолейкоза: Автореф. дис. ... д-ра мед. наук. 1998.
  10. Baccarani M. et al. Haematologica 2008; 93: 161-169.

Statistics

Views

Abstract: 145

Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2009 Vinogradova O.Y., Turkina A.G., Vorontsova A.V., Chelysheva E.Y., Gusarova G.A., Kuznetsov S.V., Goryacheva S.R., Sokolova M.A., Abakumov E.M., Stakhina O.V., Domracheva E.V., Misyurin A.V., Khoroshko N.D., Vinogradova O.Y., Turkina A.G., Vorontsova A.V., Chelysheva E.Y., Gusarova G.A., Kuznetsov S.V., Goryacheva S.R., Sokolova M.A., Abakumov E.M., Stakhina O.V., Domracheva E.V., Misyurin A.V., Khoroshko N.D.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies